FBRX's logo.
Ticker Symbol: FBRX

Forte Biosciences Inc

$3.19 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001419041

Company Profile

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. In September 2020, Forte initiated a multi-center, placebo controlled clinical trial of FB-401 which is expected to enroll pediatric, adolescent and adult AD subjects aged 2 years of age and older.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 1124 W Carson Street
CEO: Martin Duvall
Tags:
  • Health Technology
  • Biotechnology
  • Health Services
  • Medical/Nursing Services
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.60
Change: -$0.01 ( -2.47%)
Days Range: $0.60 - $0.62
Beta: 0.41
52wk. High: $1.29
52wk. Low: $0.52
Ytd. Change -40.55%
50 Day Moving Average: $0.71
200 Day Moving Average: $0.92
Shares Outstanding: 36281772

Valuation

Market Cap: 2.2B
PE Ratio: -0.04
EPS (TTM): -13.46

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A